QCOR, KERX Could Break Through Technical Barriers On Improving Fundamentals
Long Ideas - For most mutual funds, tax-loss selling must be done by the end of Monday. As a result, pressure could come off names that have had … Continue Reading
Read nowSearch Results for kerx
A Fresh Look At KERX; High Odds For Zerenex Phase III Success
Long Ideas - Keryx Biopharmaceuticals (NASDAQ:KERX) announced disappointing news earlier this year for its cancer compound perifosine, and the stock remains in the penalty box. However, the story … Continue Reading
Read now
A Quick Note on a Bizarre Conference Call
Research - Rockwell Medical (RMTI) reported fourth quarter and full-year 2015 results after the bell this evening. The accompanying conference call was bizarre, and the stock is … Continue Reading
Read now
Trillium Grabs Some New Assets, But Remains a CD-47 Story; And, Some Updates
Research - Equities remain linked at the hip to the fluctuations in oil, and Thursday marked the first meaningful decoupling in the last month. According to the Wall Street Journal, over the past 20 trading days (one month) the correlation has been 0.97, the highest in 26 years.
PremiumThere’s the Breakout We’ve All Been Looking For
Research - The breakout we’ve been looking for from the biotech sector (NASDAQ’s Biotech Index Fund (IBB) is underway coming out of large-cap bio and pharma earnings over the last two days. Beats across the board have investors enthused – at least for now – about the sector as a whole.
Premium
PropThink’s Weekly Biotech Roundup
Recap - A dual event in the obesity space this week, the U.S. FDA approved Orexigen Therapeutics’ (OREX) weight loss pill Contrave just one day before an … Continue Reading
Read now